Amy Lalonde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amy Lalonde has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Amanda C. Raff
Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, USA
1 shared publication - Anthony Almudevar
University of Rochester
1 shared publication - Carolyn Bauer
Division of Nephrology, Montefiore Medical Center/Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 615, Bronx, 10461, NY, USA
1 shared publication - Jun Sun
University of Illinois Chicago
1 shared publication - Matthew K. Abramowitz
Albert Einstein College of Medicine
1 shared publication - Michal L. Melamed
Department of Medicine (Nephrology), Albert Einstein College of Medicine/ Montefiore Medical Center, Bronx, NY
1 shared publication
Latest Publications
- 28 June 2018
- Published by Brno University of Technology in MATHEMATICS FOR APPLICATIONS
- Vol. 7 (1) , 53-62
Using the Seychelles child development study to cluster multiple outcomes into domains to improve estimation of the overall effect of mercury on neurodevelopment
Environmental exposure effects on human development can be small and difficult to detect due to the nature of observational data. In the Seychelles Child Development Study, researchers examined the effect of prenatal methylmercury exposure using a battery of tests measuring aspects of child development [23, 25]. We build a multiple outcomes model similar to that of the previous analyses (see [23, 25]); however, our multiple outcomes model makes no assumptions of relationships between the testing outcomes. Instead, the nesting of outcomes into domains is a clustering problem we address with a Dirichlet process mixture model implemented through a Bayesian MCMC approach [16]. This model provides inference for the methylmercury exposure effect as well as greater insight into the similarities and differences across the outcomes.
- 28 June 2018
- Published by Brno University of Technology in MATHEMATICS FOR APPLICATIONS
- Vol. 7 (1) , 53-62
Using the Seychelles child development study to cluster multiple outcomes into domains to improve estimation of the overall effect of mercury on neurodevelopment
Environmental exposure effects on human development can be small and difficult to detect due to the nature of observational data. In the Seychelles Child Development Study, researchers examined the effect of prenatal methylmercury exposure using a battery of tests measuring aspects of child development [23, 25]. We build a multiple outcomes model similar to that of the previous analyses (see [23, 25]); however, our multiple outcomes model makes no assumptions of relationships between the testing outcomes. Instead, the nesting of outcomes into domains is a clustering problem we address with a Dirichlet process mixture model implemented through a Bayesian MCMC approach [16]. This model provides inference for the methylmercury exposure effect as well as greater insight into the similarities and differences across the outcomes.
- Open Access
- 17 February 2017
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17 (1) , 33
High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5
Claudins are a family of integral membrane proteins and are components of tight junctions (TJs). Many TJ proteins are known to tighten the cell structure and maintain a barrier. Claudin-2 forms gated paracellular channels and allows sodium ions and other small positively charged ions to cross between adjacent cells. Recently, we found that vitamin D receptor (VDR) enhanced Claudin-2 expression in colon and that bile salt receptors VDR and Takeda G-protein coupled receptor5 (TGR5) were highly expressed in esophageal adenocarcinoma (EAC) and precancerous lesions. Here, we examined the expression of Claudin-2 in EAC and precancerous lesions and its association with VDR and TGR5 expression. Claudin-2 expression was examined by immunohistochemistry on tissue microarrays, containing EAC, high grade dysplasia (HGD), low grade dysplasia (LGD), Barrett’s esophagus (BE), columnar cell metaplasia (CM), squamous cell carcinoma (SCC), and squamous epithelium (SE) cases. Intensity (0 to 3) and percentage were scored for each case. High expression was defined as 2–3 intensity in ≥ 10% of cells. Claudin-2 was highly expressed in 77% EAC (86/111), 38% HGD (5/13), 61% LGD (17/28), 46% BE (18/39), 45% CM (29/65), 88% SCC (23/26), and 14% SE (11/76). It was significantly more highly-expressed in EAC, SCC and glandular lesions than in SE and more in EAC than in BE and CM. A significant association was found between Claudin-2 expression and VDR and TGR5 expression. No significant association was found between expression of Claudin-2 and age, gender, grade, stage, or patients’ survival time in EAC and SCC. We conclude that Claudin-2 expression is significantly associated with bile acid receptors VDR and TGR5 expression. Our studies identify a novel role of a tight junction protein in the development and progression of esophageal mucosal metaplasia, dysplasia and carcinoma.
- 17 February 2017
- Published by Springer Nature in BMC Gastroenterology
- Vol. 17 (1) , 33
Open AccessHigh expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5
Claudins are a family of integral membrane proteins and are components of tight junctions (TJs). Many TJ proteins are known to tighten the cell structure and maintain a barrier. Claudin-2 forms gated paracellular channels and allows sodium ions and other small positively charged ions to cross between adjacent cells. Recently, we found that vitamin D receptor (VDR) enhanced Claudin-2 expression in colon and that bile salt receptors VDR and Takeda G-protein coupled receptor5 (TGR5) were highly expressed in esophageal adenocarcinoma (EAC) and precancerous lesions. Here, we examined the expression of Claudin-2 in EAC and precancerous lesions and its association with VDR and TGR5 expression. Claudin-2 expression was examined by immunohistochemistry on tissue microarrays, containing EAC, high grade dysplasia (HGD), low grade dysplasia (LGD), Barrett’s esophagus (BE), columnar cell metaplasia (CM), squamous cell carcinoma (SCC), and squamous epithelium (SE) cases. Intensity (0 to 3) and percentage were scored for each case. High expression was defined as 2–3 intensity in ≥ 10% of cells. Claudin-2 was highly expressed in 77% EAC (86/111), 38% HGD (5/13), 61% LGD (17/28), 46% BE (18/39), 45% CM (29/65), 88% SCC (23/26), and 14% SE (11/76). It was significantly more highly-expressed in EAC, SCC and glandular lesions than in SE and more in EAC than in BE and CM. A significant association was found between Claudin-2 expression and VDR and TGR5 expression. No significant association was found between expression of Claudin-2 and age, gender, grade, stage, or patients’ survival time in EAC and SCC. We conclude that Claudin-2 expression is significantly associated with bile acid receptors VDR and TGR5 expression. Our studies identify a novel role of a tight junction protein in the development and progression of esophageal mucosal metaplasia, dysplasia and carcinoma.
- Open Access
- 5 August 2016
- Published by Springer Nature in BMC Nephrology
- Vol. 17 (1) , 1-7
Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study
The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels in patients with CKD. This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between 15–45 mL/min/1.73 m2 and serum bicarbonate between 20–24 mEq/L were treated with placebo for 2 weeks, followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after 6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before and after sodium bicarbonate. After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7–267.43) to 191.4 RU/mL (IQR 132.6–316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D. FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors. The study was registered at ClinicalTrials.gov ( NCT00888290 ) on April 23, 2009.
- 5 August 2016
- Published by Springer Nature in BMC Nephrology
- Vol. 17 (1) , 1-7
Open AccessEffect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study
The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels in patients with CKD. This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between 15–45 mL/min/1.73 m2 and serum bicarbonate between 20–24 mEq/L were treated with placebo for 2 weeks, followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after 6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before and after sodium bicarbonate. After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL (IQR 107.7–267.43) to 191.4 RU/mL (IQR 132.6–316.9) (p = 0.048) and this persisted after excluding participants who received activated vitamin D. FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors. The study was registered at ClinicalTrials.gov ( NCT00888290 ) on April 23, 2009.